Show simple item record

dc.contributor.authorRuiz, EJ
dc.contributor.authorDiefenbacher, ME
dc.contributor.authorNelson, JK
dc.contributor.authorSancho, R
dc.contributor.authorPucci, F
dc.contributor.authorChakraborty, A
dc.contributor.authorMoreno, P
dc.contributor.authorAnnibaldi, A
dc.contributor.authorLiccardi, G
dc.contributor.authorEncheva, V
dc.contributor.authorMitter, R
dc.contributor.authorRosenfeldt, M
dc.contributor.authorSnijders, AP
dc.contributor.authorMeier, P
dc.contributor.authorCalzado, MA
dc.contributor.authorBehrens, A
dc.date.accessioned2020-08-28T10:25:42Z
dc.date.issued2019-02-04
dc.identifier.citationThe Journal of experimental medicine, 2019, 216 (2), pp. 450 - 465
dc.identifier.issn0022-1007
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4055
dc.identifier.eissn1540-9538
dc.identifier.doi10.1084/jem.20180742
dc.description.abstractLung squamous cell carcinoma (LSCC) and adenocarcinoma (LADC) are the most common lung cancer subtypes. Molecular targeted treatments have improved LADC patient survival but are largely ineffective in LSCC. The tumor suppressor FBW7 is commonly mutated or down-regulated in human LSCC, and oncogenic KRasG12D activation combined with Fbxw7 inactivation in mice (KF model) caused both LSCC and LADC. Lineage-tracing experiments showed that CC10+, but not basal, cells are the cells of origin of LSCC in KF mice. KF LSCC tumors recapitulated human LSCC resistance to cisplatin-based chemotherapy, and we identified LUBAC-mediated NF-κB signaling as a determinant of chemotherapy resistance in human and mouse. Inhibition of NF-κB activation using TAK1 or LUBAC inhibitors resensitized LSCC tumors to cisplatin, suggesting a future avenue for LSCC patient treatment.
dc.formatPrint-Electronic
dc.format.extent450 - 465
dc.languageeng
dc.language.isoeng
dc.publisherROCKEFELLER UNIV PRESS
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectAnimals
dc.subjectHumans
dc.subjectMice
dc.subjectCarcinoma, Squamous Cell
dc.subjectLung Neoplasms
dc.subjectCisplatin
dc.subjectMultienzyme Complexes
dc.subjectDrug Resistance, Neoplasm
dc.subjectProto-Oncogene Proteins p21(ras)
dc.subjectUbiquitination
dc.subjectAdenocarcinoma of Lung
dc.titleLUBAC determines chemotherapy resistance in squamous cell lung cancer.
dc.typeJournal Article
dcterms.dateAccepted2018-12-18
rioxxterms.versionofrecord10.1084/jem.20180742
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2019-02
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfThe Journal of experimental medicine
pubs.issue2
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR
pubs.publication-statusPublished
pubs.volume216
pubs.embargo.termsNot known
dc.contributor.icrauthorMeier, Pascal
dc.contributor.icrauthorBehrens, Axel


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0